ApyraMed - Model MV-002 - Cancer Immunotherapy with Immune Checkpoint Inhibitors (ICIs)

Cancer immunotherapy has therapeutic efficacy in a limited number of patients. Cancer immunotherapy with immune checkpoint inhibitors (ICIs) increases anti-tumor immunity by blocking molecules that suppress anti-tumor activity. However, only a limited fraction of patients benefits from the therapeutic response obtained with these biologic drugs. Therefore, factors that could improve the therapeutic outcome are needed. In patients responsive to the therapy with ICIs, the tumor microenvironment is replenished with fresh T cells with self-renewing capacity from sites outside the tumor. This phenomenon appears to be a key factor in explaining the clinical benefit of ICIs. ApyraMed has shown to promote the effective generation of self-renewing anti-tumor cytotoxic T cells and synergize with ICIs in controlling tumor growth, thus resulting in superior survival in experimental models of solid tumors.